

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10554984/publications.pdf>

Version: 2024-02-01

355  
papers

36,866  
citations

5876

81  
h-index

3312

184  
g-index

360  
all docs

360  
docs citations

360  
times ranked

27019  
citing authors

#	ARTICLE	IF	CITATIONS
1	Coronary Atherosclerotic Plaque Regression. <i>Journal of the American College of Cardiology</i> , 2022, 79, 66-82.	1.2	44
2	HbA1c, Coronary atheroma progression and cardiovascular outcomes. <i>American Journal of Preventive Cardiology</i> , 2022, 9, 100317.	1.3	4
3	Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1308-1321.	2.3	137
4	Targeting triglycerides to lower residual cardiovascular risk. <i>Expert Review of Cardiovascular Therapy</i> , 2022, , 1-7.	0.6	2
5	Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 709-711.	2.3	2
6	Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity. <i>Journal of the American Heart Association</i> , 2022, 11, e024754.	1.6	13
7	Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol <math>\leq 55\text{ mg/dL}</math>. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1166-1169.	2.3	2
8	Optical coherence tomography in coronary atherosclerosis assessment and intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 684-703.	6.1	106
9	Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. <i>American Heart Journal</i> , 2022, 251, 1-12.	1.2	4
10	Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician. <i>Journal of Paediatrics and Child Health</i> , 2022, 58, 1297-1312.	0.4	6
11	New Cardiovascular Risk Assessment Techniques for Primary Prevention. <i>Journal of the American College of Cardiology</i> , 2022, 80, 373-387.	1.2	5
12	Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging. <i>American Journal of Preventive Cardiology</i> , 2022, 11, 100366.	1.3	12
13	Cardiovascular bioimaging of nitric oxide: Achievements, challenges, and the future. <i>Medicinal Research Reviews</i> , 2021, 41, 435-463.	5.0	21
14	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127.	1.2	60
15	Oral Calcium Supplements Associate With Serial Coronary Calcification. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 259-268.	2.3	15
16	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. <i>Heart Lung and Circulation</i> , 2021, 30, 324-349.	0.2	51
17	Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 120-129.	0.7	41
18	Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. <i>Atherosclerosis</i> , 2021, 320, 122-128.	0.4	45

#	ARTICLE	IF	CITATIONS
19	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 2167-2182.e22.	13.5	131
20	Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1334.	3.8	2
21	Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. <i>Internal Medicine Journal</i> , 2021, 51, 769-779.	0.5	4
22	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 125.	2.7	11
23	Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100151.	1.3	3
24	Can CMR Elucidate the Cardiovascular Benefit of SGLT2 Inhibitors?. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1174-1176.	2.3	1
25	Association Between Achieved $\Omega$ -3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk. <i>JAMA Cardiology</i> , 2021, 6, 910.	3.0	52
26	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	13.9	2,143
27	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	1.0	117
28	Plaque microstructures during metformin therapy in type 2 diabetic subjects with coronary artery disease: optical coherence tomography analysis. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 12, 0-0.	0.7	5
29	An update on emerging drugs for the treatment of hypercholesterolemia. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 363-369.	1.0	4
30	Quantitative and Qualitative Coronary Plaque Assessment Using Computed Tomography Coronary Angiography: A Comparison With Intravascular Ultrasound. <i>Heart Lung and Circulation</i> , 2020, 29, 883-893.	0.2	6
31	High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 11-18.	1.0	0
32	Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 30-38.	2.2	4
33	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	3.0	169
34	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. <i>American Heart Journal</i> , 2020, 221, 60-66.	1.2	5
35	Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1091-1100.	0.8	61
36	The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. <i>Diabetes Care</i> , 2020, 43, e22-e24.	4.3	9

#	ARTICLE	IF	CITATIONS
37	Using genetics to guide treatment and drug development in cardiovascular medicine: time to reveal the proof in the pudding. <i>Cardiovascular Research</i> , 2020, 116, e30-e32.	1.8	1
38	Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy. <i>Journal of the American Heart Association</i> , 2020, 9, e014328.	1.6	11
39	Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound. <i>Journal of the American Heart Association</i> , 2020, 9, e018023.	1.6	12
40	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	2.9	93
41	Progression of coronary atherosclerosis in patients without standard modifiable risk factors. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100116.	1.3	12
42	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2268.	3.8	540
43	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821
44	The role of intracoronary imaging in translational research. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1480-1507.	0.7	3
45	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100091.	1.3	2
46	Tackling cardiometabolic risk in the Asia Pacific region. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100096.	1.3	5
47	Translating evidence from clinical trials of omega-3 fatty acids to clinical practice. <i>Future Cardiology</i> , 2020, 16, 343-350.	0.5	0
48	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000943.	1.2	15
49	The mystery of evacetrapib - why are CETP inhibitors failing?. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 127-130.	0.6	12
50	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1565.	3.8	103
51	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1136.	3.0	59
52	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.	4.3	21
53	Progression of ultrasound plaque attenuation and low echogenicity associates with major adverse cardiovascular events. <i>European Heart Journal</i> , 2020, 41, 2965-2973.	1.0	19
54	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	1.0	776

#	ARTICLE	IF	CITATIONS
55	The fish-oil paradox. <i>Current Opinion in Lipidology</i> , 2020, 31, 356-361.	1.2	5
56	Current and Emerging Therapies for Atherosclerosis. , 2020, , 71-88.		0
57	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <i>Lancet</i> , The, 2019, 394, 697-708.	6.3	67
58	Vascular calcification in response to pharmacological interventions. , 2019, , 181-189.		0
59	Chronic kidney disease and coronary atherosclerosis: evidences from intravascular imaging. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 707-716.	0.6	4
60	Plaque Calcification. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1902-1910.	1.1	43
61	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1381.	3.8	144
62	Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. <i>Atherosclerosis</i> , 2019, 290, 59-65.	0.4	30
63	Associations of ABCG1-mediated cholesterol efflux capacity with coronary artery lipid content assessed by near-infrared spectroscopy. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 310-318.	0.7	9
64	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019, 217, 72-83.	1.2	45
65	Association of Triglyceride-Lowering <i>LPL</i> Variants and LDL-Câ€“Lowering <i>LDLR</i> Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 364.	3.8	460
66	Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 343-348.	1.0	7
67	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2819-2828.	1.2	64
68	Status of PCSK9 Monoclonal Antibodies in Australia. <i>Heart Lung and Circulation</i> , 2019, 28, 1571-1579.	0.2	9
69	Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 171-177.	0.9	9
70	The time for lipoprotein(a) based intervention has arrived: where will the light shine?. <i>Journal of Thoracic Disease</i> , 2019, 11, S433-S436.	0.6	3
71	Serial Coronary Plaque Assessment Using Computed Tomography Coronary Angiography. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e008404.	1.3	11
72	The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. <i>Current Cardiology Reports</i> , 2019, 21, 18.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2019, 4, 314.	3.0	79
74	Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography. <i>Atherosclerosis</i> , 2019, 284, 24-30.	0.4	37
75	Mendelian Randomization Study of <i>ACLY</i> and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1033-1042.	13.9	216
76	Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes. <i>JAMA Cardiology</i> , 2019, 4, 437.	3.0	59
77	Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e013790.	1.6	3
78	The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 49-57.	1.0	31
79	Combining cholesterol-lowering strategies with imaging data: a visible benefit?. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 365-379.	0.8	1
80	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 113-131.	1.0	4
81	Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 229-235.	1.0	0
82	HDL and cardiovascular disease. <i>Pathology</i> , 2019, 51, 142-147.	0.3	56
83	Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. <i>Clinical Biochemistry</i> , 2019, 64, 24-29.	0.8	36
84	Inflammatory Markers and Novel Risk Factors. <i>Contemporary Cardiology</i> , 2019, , 87-98.	0.0	0
85	Treating Dyslipidemia in Type 2 Diabetes. <i>Cardiology Clinics</i> , 2018, 36, 233-239.	0.9	11
86	High-Density Lipoprotein Infusions. <i>Cardiology Clinics</i> , 2018, 36, 311-315.	0.9	3
87	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , 2018, 202, 89-96.	1.2	13
88	Evaluation of human coronary vasodilator function predicts future coronary atheroma progression. <i>Heart</i> , 2018, 104, 1439-1446.	1.2	1
89	Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1721-1723.	2.3	5
90	Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. <i>European Heart Journal</i> , 2018, 39, 2551-2558.	1.0	61

#	ARTICLE	IF	CITATIONS
91	Intravascular Ultrasound Studies of Plaque Progression and Regression. <i>Cardiology Clinics</i> , 2018, 36, 329-334.	0.9	0
92	Myeloperoxidase modification of high-density lipoprotein suppresses human endothelial cell proliferation and migration via inhibition of ERK1/2 and Akt activation. <i>Atherosclerosis</i> , 2018, 273, 75-83.	0.4	9
93	Advances in lipid-lowering therapy through gene-silencing technologies. <i>Nature Reviews Cardiology</i> , 2018, 15, 261-272.	6.1	101
94	Managing Dyslipidemia in Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 153-173.	1.2	24
95	Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. <i>Cardiology</i> , 2018, 140, 30-34.	0.6	5
96	<i>ADCY9</i> Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease. <i>JAMA Cardiology</i> , 2018, 3, 401.	3.0	42
97	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 391.	3.0	65
98	Warfarin Use Is Associated With Progressive Coronary Arterial Calcification. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1315-1323.	2.3	44
99	Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 435-443.	0.7	7
100	Rationale and design of a trial to personalize risk assessment in familial coronary artery disease. <i>American Heart Journal</i> , 2018, 199, 22-30.	1.2	14
101	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 164.	3.0	68
102	Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 109-115.	1.0	92
103	Tackling Cardiovascular Risk in Type 2 Diabetes: Does Baseline Glucose Control Matter?. <i>EClinicalMedicine</i> , 2018, 4-5, 6-7.	3.2	0
104	Extent of coronary atherosclerosis and arterial remodelling in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 405-413.	0.7	4
105	High-Density Lipoprotein "Targeted Therapies" Not Dead Yet "Reply". <i>JAMA Cardiology</i> , 2018, 3, 1255.	3.0	1
106	Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 259-266.	0.8	1
107	Monitoring the Response to Statin Therapy. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1485-1486.	2.3	2
108	Translating Evidence of HDL and Plaque Regression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1961-1968.	1.1	25

#	ARTICLE	IF	CITATIONS
109	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. <i>Journal of the American Heart Association</i> , 2018, 7, e009778.	1.6	67
110	Effect of Evolocumab on Coronary Plaque Composition. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2012-2021.	1.2	95
111	Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors. <i>European Cardiology Review</i> , 2018, 13, 9.	0.7	1
112	High-Density Lipoproteins and Apolipoprotein A-I Improve Stent Biocompatibility. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1691-1701.	1.1	16
113	Effect of Serial Infusions of CER-001, a Pre-Î² High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial. <i>JAMA Cardiology</i> , 2018, 3, 815.	3.0	135
114	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial. <i>JAMA Cardiology</i> , 2018, 3, 806.	3.0	129
115	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2522-2533.	1.8	7
116	The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1680.	1.8	41
117	Exploring the Roles of CREBRF and TRIM2 in the Regulation of Angiogenesis by High-Density Lipoproteins. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1903.	1.8	16
118	The relationship between segmental wall shear stress and lipid core plaque derived from near-infrared spectroscopy. <i>Atherosclerosis</i> , 2018, 275, 68-73.	0.4	17
119	Coronary arterial calcification: A review of mechanisms, promoters and imaging. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 491-501.	2.3	68
120	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. <i>Clinical Cardiology</i> , 2018, 41, 1281-1288.	0.7	151
121	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. <i>Diabetes Care</i> , 2018, 41, 1792-1800.	4.3	25
122	CETP Inhibition and HDL Cholesterol: A Story of CV Risk or CV Benefit, or Both. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 297-300.	2.3	22
123	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	2
124	What role for lipoprotein(a) in clinical practice?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 487-489.	5.5	3
125	Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. <i>Internal Medicine Journal</i> , 2017, 47, 856-865.	0.5	18
126	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	1.0	2,292



#	ARTICLE	IF	CITATIONS
127	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , 2017, 261, 12-18.	0.4	32
128	PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. <i>BioDrugs</i> , 2017, 31, 167-174.	2.2	14
129	Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 447-452.	1.0	2
130	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1933-1942.	13.9	593
131	Will genetic studies deliver the next generation of cardioprotective therapies?. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 489-491.	0.8	1
132	Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. <i>Atherosclerosis</i> , 2017, 265, 54-59.	0.4	29
133	In vivo visualization of lipid coronary atheroma with intravascular near-infrared spectroscopy. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 775-785.	0.6	11
134	Implications of GLAGOV study. <i>Current Opinion in Lipidology</i> , 2017, 28, 465-469.	1.2	6
135	High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy. <i>Atherosclerosis</i> , 2017, 265, 110-116.	0.4	15
136	Plaque burden, microstructures and compositions underachieving very low LDL-C levels. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 122-132.	1.2	7
137	Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. <i>Atherosclerosis</i> , 2017, 263, 137-144.	0.4	35
138	PCSK9 Inhibitors: Treating the Right Patients in Daily Practice. <i>Current Cardiology Reports</i> , 2017, 19, 66.	1.3	1
139	Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 373-381.	0.8	23
140	Intravascular Ultrasound and Near-Infrared Spectroscopic Characterization of Thin-Cap Fibroatheroma. <i>American Journal of Cardiology</i> , 2017, 119, 372-378.	0.7	13
141	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 947.	3.8	247
142	Anacetrapib as a potential cardioprotective strategy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3497-3502.	2.0	9
143	Lipid Lowering Therapy to Modify Plaque Microstructures:. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 360-372.	0.9	7
144	Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis. <i>Archives of Medical Science</i> , 2017, 1, 210-214.	0.4	4

#	ARTICLE	IF	CITATIONS
145	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 45-51.	0.7	49
146	Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 252-263.	0.7	42
147	Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond. <i>Archives of Medical Science</i> , 2016, 6, 1302-1307.	0.4	14
148	Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 282-303.	0.7	13
149	Hypertriglyceridemia and Cardiovascular Diseases: Revisited. <i>Korean Circulation Journal</i> , 2016, 46, 135.	0.7	39
150	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016, 176, 83-92.	1.2	45
151	Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. <i>Journal of Clinical Lipidology</i> , 2016, 10, 519-527.e4.	0.6	42
152	A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2016, 117, 1444-1448.	0.7	78
153	CETP Inhibition in CVD Prevention: an Actual Appraisal. <i>Current Cardiology Reports</i> , 2016, 18, 43.	1.3	14
154	Comparing Coronary Atheroma Progression Rates and Coronary Events in the United States, Canada, Latin America, and Europe. <i>American Journal of Cardiology</i> , 2016, 118, 1616-1623.	0.7	4
155	Non-HDL Cholesterol and Triglycerides. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2220-2228.	1.1	119
156	Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	49
157	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2488-2490.	1.2	4
158	Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. <i>Atherosclerosis</i> , 2016, 254, 78-84.	0.4	18
159	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2373.	3.8	813
160	Clinical trials with cholesteryl ester transfer protein inhibitors. <i>Current Opinion in Lipidology</i> , 2016, 27, 545-549.	1.2	15
161	Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 212-217.	1.4	99
162	Non-invasive volumetric assessment of aortic atheroma: a core laboratory validation using computed tomography angiography. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 121-129.	0.7	3

#	ARTICLE	IF	CITATIONS
163	Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review. <i>Current Medical Research and Opinion</i> , 2016, 32, 1143-1150.	0.9	7
164	Confirmation of the Intracoronary Near-Infrared Spectroscopy Threshold of Lipid-Rich Plaques That Underlie ST-Segmentâ€Elevation Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1010-1015.	1.1	45
165	Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 744-747.	0.8	47
166	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 55-65.	1.0	82
167	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 474-485.	0.8	12
168	HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 34-43.	0.7	13
169	Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. <i>Journal of the Japanese Coronary Association</i> , 2016, 22, 217-227.	0.0	0
170	Statin-induced coronary artery disease regression rates differ in men and women. <i>Current Opinion in Lipidology</i> , 2015, 26, 276-281.	1.2	12
171	Acute high-density lipoprotein therapies. <i>Current Opinion in Lipidology</i> , 2015, 26, 521-525.	1.2	3
172	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. <i>Cardiovascular Endocrinology</i> , 2015, 4, 45-52.	0.8	10
173	Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?. <i>Vascular Health and Risk Management</i> , 2015, 11, 203.	1.0	6
174	Position paper Statin intolerance â€E an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.4	311
175	To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis. <i>Atherosclerosis</i> , 2015, 241, 450-454.	0.4	17
176	Atheroma Progression in Hyporesponders to Statin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 990-995.	1.1	58
177	CYPâ€Emediated drugâ€Edrug interactions with evacetrapib, an investigational CETP inhibitor: <i>in vitro</i> prediction and clinical outcome. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1388-1398.	1.1	9
178	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2201-2210.	1.2	105
179	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?. <i>Circulation</i> , 2015, 132, 423-432.	1.6	24
180	Favorable Impact on LDL Particle Size in Response to Treatment With Pioglitazone is Associated With Less Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 328-329.	1.2	7

#	ARTICLE	IF	CITATIONS
181	Response to Comment on Stegman et al. High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. <i>Diabetes Care</i> 2014;37:3114-3120. <i>Diabetes Care</i> , 2015, 38, e28-e29.	4.3	2
182	Redox biomarkers in cardiovascular medicine. <i>European Heart Journal</i> , 2015, 36, 1576-1582.	1.0	61
183	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	1.0	117
184	Lipid Biomarkers and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1296-1297.	1.2	3
185	Impact of Statins on Serial Coronary Calcification During Atheroma Progression and Regression. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1273-1282.	1.2	467
186	Men and women – similar but not identical: insights into LDL-lowering therapy in women from the Cholesterol Treatment Trialists Collaboration. <i>Future Cardiology</i> , 2015, 11, 511-515.	0.5	3
187	Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. <i>Atherosclerosis</i> , 2015, 243, 553-559.	0.4	3
188	Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1331-1339.	0.8	7
189	Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. <i>Atherosclerosis</i> , 2015, 242, 490-495.	0.4	43
190	Statins and CETP Inhibitors: Anacetrapib and Evacetrapib: The Last Hope?. , 2015, , 65-71.		1
191	Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. <i>American Heart Journal</i> , 2015, 170, 1061-1069.	1.2	74
192	Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2423-2431.	1.1	48
193	Coronary atheroma composition and its association with segmental endothelial dysfunction in non-ST segment elevation myocardial infarction: novel insights with radiofrequency (iMAP) intravascular ultrasonography. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 247-257.	0.7	5
194	Ongoing challenges for pharmacotherapy for dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 347-356.	0.9	6
195	Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 280-9.	0.7	16
196	Examining controversies and new frontiers in lipid management. <i>Clinical Lipidology</i> , 2014, 9, 587-595.	0.4	0
197	Left main coronary arterial endothelial function and heterogenous segmental epicardial vasomotor reactivity in vivo: novel insights with intravascular ultrasonography. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1270-1280.	0.5	1
198	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 252.	3.8	270

#	ARTICLE	IF	CITATIONS
199	Imaging of atherosclerotic plaques in obesity: excessive fat accumulation, plaque progression and vulnerability. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1471-1489.	0.6	6
200	Evolving targets for lipid-modifying therapy. <i>EMBO Molecular Medicine</i> , 2014, 6, 1215-1230.	3.3	11
201	Effect of Alogliptin on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1515.	3.8	206
202	Update in Therapeutic Approaches to Plaque Stabilization. <i>Current Atherosclerosis Reports</i> , 2014, 16, 392.	2.0	4
203	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014, 35, 960-968.	1.0	270
204	High-Risk Coronary Atheroma. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1134-1140.	1.2	32
205	Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 380-388.	0.5	139
206	Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. <i>American Journal of Cardiology</i> , 2014, 114, 1465-1472.	0.7	42
207	Is Lp(a) Ready for Prime Time?—. <i>Journal of the American College of Cardiology</i> , 2014, 64, 861-862.	1.2	2
208	Lipid pharmacotherapy for treatment of atherosclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1119-1125.	0.9	13
209	Relation of High-Density Lipoprotein Cholesterol:Apolipoprotein A-I Ratio to Progression of Coronary Atherosclerosis in Statin-Treated Patients. <i>American Journal of Cardiology</i> , 2014, 114, 681-685.	0.7	18
210	High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. <i>Diabetes Care</i> , 2014, 37, 3114-3120.	4.3	50
211	Sex-Related Differences of Coronary Atherosclerosis Regression Following Maximally Intensive Statin Therapy. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1013-1022.	2.3	54
212	Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2465-2472.	1.1	41
213	Progression of coronary atherosclerosis in stable patients with ultrasonic features of high-risk plaques. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1035-1041.	0.5	25
214	Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1298-1306.	1.1	59
215	Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: Insights from intravascular ultrasound. <i>Atherosclerosis</i> , 2014, 232, 377-383.	0.4	40
216	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 455-463.	5.5	84

#	ARTICLE	IF	CITATIONS
217	Frequency-Domain Optical Coherence Tomographic Analysis of Plaque Microstructures at Nonculprit Narrowings in Patients Receiving Potent Statin Therapy. <i>American Journal of Cardiology</i> , 2014, 114, 549-554.	0.7	37
218	Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER. <i>IJC Metabolic &amp; Endocrine</i> , 2014, 5, 61-66.	0.5	1
219	Spotty calcification and plaque vulnerability in vivo: frequency-domain optical coherence tomography analysis. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 460-9.	0.7	63
220	Residual Risk and Biology of the Disease: Implications for Plaque Imaging. <i>Contemporary Cardiology</i> , 2014, , 1-21.	0.0	1
221	Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy. <i>Journal of the Japanese Coronary Association</i> , 2014, 20, 282-294.	0.0	0
222	Monitoring the Progression and Regression of Coronary Atherosclerosis with Intravascular Ultrasound. <i>Contemporary Cardiology</i> , 2014, , 67-79.	0.0	0
223	Evaluation of the dual peroxisome proliferator-activated receptor $\alpha/\beta$ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial. <i>American Heart Journal</i> , 2013, 166, 429-434.e1.	1.2	39
224	A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). <i>Clinical Therapeutics</i> , 2013, 35, 1400-1411.e3.	1.1	94
225	Left Main Coronary Atherosclerosis Progression, Constrictive Remodeling, and Clinical Events. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 29-35.	1.1	36
226	Detection by Near-Infrared Spectroscopy of Large Lipid Core Plaques at Culprit Sites in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 838-846.	1.1	169
227	Intracoronary Optical Coherence Tomography. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1759-1760.	1.2	0
228	Lipidomics: Opportunities to Identify New Causal Mechanisms and Therapeutics for Atherosclerosis. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 60-65.	0.8	0
229	Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <math><70\text{ mg/dl}</math> or $\geq 50\%$ reduction in high-risk patients: Results from VOYAGER. <i>Atherosclerosis</i> , 2013, 228, 265-269.	0.4	20
230	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy”A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	3.1	90
231	Exploring coronary atherosclerosis with intravascular imaging. <i>International Journal of Cardiology</i> , 2013, 168, 670-679.	0.8	44
232	Epanova <sup>®</sup> and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. <i>Future Cardiology</i> , 2013, 9, 177-186.	0.5	12
233	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	0.9	36
234	Factors underlying regression of coronary atheroma with potent statin therapy. <i>European Heart Journal</i> , 2013, 34, 1818-1825.	1.0	61

#	ARTICLE	IF	CITATIONS
235	Coronary Endothelium-Dependent Vasoreactivity and Atheroma Volume in Subjects With Stable, Minimal Angiographic Disease Versus Non-“ST-Segment” Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 674-682.	1.3	8
236	Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. <i>European Heart Journal</i> , 2013, 34, 3182-3190.	1.0	86
237	Imaging coronary atherosclerosis: is there space for magnetic resonance imaging?. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 383-385.	0.6	1
238	Is It Time for HDL to Change Its Tune?. <i>Circulation</i> , 2013, 128, 1175-1176.	1.6	4
239	Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1135.	3.8	67
240	Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: An analysis from the VOYAGER database. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 1080-1087.	0.8	22
241	Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 209-217.	0.8	26
242	C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy. <i>Circulation</i> , 2013, 128, 2395-2403.	1.6	109
243	Imaging Progression of Coronary Atherosclerosis. <i>Circulation Journal</i> , 2013, 77, 3-10.	0.7	9
244	Progression of coronary atherosclerosis in African-American patients. <i>Cardiovascular Diagnosis and Therapy</i> , 2013, 3, 161-9.	0.7	7
245	Peroxisome proliferator-activated receptor (PPAR $\alpha/\delta$ ) agonists as a potential target to reduce cardiovascular risk in diabetes. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 89-94.	0.9	19
246	Predicting the Future. <i>Circulation</i> , 2012, 126, 161-162.	1.6	3
247	Coronary $\beta_2$ -adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study. <i>European Heart Journal</i> , 2012, 33, 495-504.	1.0	36
248	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2089-2099.	13.9	1,754
249	Optimizing Outcomes During Left Main Percutaneous Coronary Intervention With Intravascular Ultrasound and Fractional Flow Reserve. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 697-707.	1.1	72
250	Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 349-358.	1.3	14
251	The emerging role of plasma lipidomics in cardiovascular drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 63-72.	2.5	20
252	Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study. <i>American Heart Journal</i> , 2012, 163, 735-740.	1.2	10

#	ARTICLE	IF	CITATIONS
253	â€œFramingâ€the Vessel. Journal of the American College of Cardiology, 2012, 59, 1038-1039.	1.2	5
254	Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis. Journal of the American College of Cardiology, 2012, 59, 1592-1597.	1.2	164
255	Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. Progress in Lipid Research, 2012, 51, 314-324.	5.3	187
256	Current imaging modalities for atherosclerosis. Expert Review of Cardiovascular Therapy, 2012, 10, 457-471.	0.6	7
257	ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies. Cardiovascular Drugs and Therapy, 2012, 26, 181-187.	1.3	80
258	Evacetrapib. Current Cardiology Reports, 2012, 14, 245-250.	1.3	13
259	The Distinctive Nature of Atherosclerotic Vascular Disease in Diabetes: Pathophysiological and Morphological Insights. Current Diabetes Reports, 2012, 12, 280-285.	1.7	24
260	Intracoronary IVUS for Evaluation of Atherosclerosis Progression. Current Cardiovascular Imaging Reports, 2012, 5, 239-248.	0.4	0
261	ETC-216 for coronary artery disease. Expert Opinion on Biological Therapy, 2011, 11, 387-394.	1.4	25
262	Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients. Journal of the American College of Cardiology, 2011, 57, 153-159.	1.2	106
263	Peripheral Arterial Disease and Progression of Coronary Atherosclerosis. Journal of the American College of Cardiology, 2011, 57, 1220-1225.	1.2	84
264	Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 57, 1111-1119.	1.2	161
265	Will apoA-I-based therapies step up to cure coronary artery disease?. Expert Review of Cardiovascular Therapy, 2011, 9, 1367-1370.	0.6	0
266	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine, 2011, 365, 2078-2087.	13.9	731
267	Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. Expert Review of Cardiovascular Therapy, 2011, 9, 1383-1390.	0.6	7
268	Intravascular imaging of vulnerable coronary plaque: current and future concepts. Nature Reviews Cardiology, 2011, 8, 131-139.	6.1	84
269	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Current Medical Research and Opinion, 2011, 27, 1119-1129.	0.9	43
270	High-Density Lipoprotein: Is the Good Cholesterol Turning Bad?. Current Cardiovascular Risk Reports, 2011, 5, 18-28.	0.8	2



#	ARTICLE	IF	CITATIONS
271	Apo A-I Modulating Therapies. <i>Current Cardiology Reports</i> , 2011, 13, 537-543.	1.3	5
272	Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2099-109.	3.8	374
273	Risk Prediction with Serial Myeloperoxidase Monitoring in Patients with Acute Chest Pain. <i>Clinical Chemistry</i> , 2011, 57, 1762-1770.	1.5	41
274	A Prospective, Randomized Trial of Single-Drug Versus Dual-Drug Immunosuppression in Heart Transplantation. <i>Circulation: Heart Failure</i> , 2011, 4, 129-137.	1.6	62
275	Plasma Myeloperoxidase Predicts Incident Cardiovascular Risks in Stable Patients Undergoing Medical Management for Coronary Artery Disease. <i>Clinical Chemistry</i> , 2011, 57, 33-39.	1.5	86
276	Inflammatory Markers and Novel Risk Factors. , 2011, , 107-123.		0
277	Intracoronary Ultrasound in Assessing Efficacy of Cardiovascular Drugs. <i>Current Cardiovascular Imaging Reports</i> , 2010, 3, 190-196.	0.4	0
278	Statin Effects on Both Low-Density Lipoproteins and High-Density Lipoproteins: Is There a Dual Benefit?. <i>Current Atherosclerosis Reports</i> , 2010, 12, 14-19.	2.0	4
279	Lessons from Coronary Intravascular Ultrasound on the Importance of Raising High-Density Lipoprotein Cholesterol. <i>Current Atherosclerosis Reports</i> , 2010, 12, 301-307.	2.0	8
280	Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER). <i>American Journal of Cardiology</i> , 2010, 105, 69-76.	0.7	206
281	Plaque Progression in Coronary Arteries With Minimal Luminal Obstruction in Intravascular Ultrasound Atherosclerosis Trials. <i>American Journal of Cardiology</i> , 2010, 105, 1679-1683.	0.7	13
282	Comparison of Rates of Progression of Coronary Atherosclerosis in Patients With Diabetes Mellitus Versus Those With the Metabolic Syndrome. <i>American Journal of Cardiology</i> , 2010, 105, 1735-1739.	0.7	32
283	Strategies for the development of new PPAR agonists in diabetes. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, s32-s37.	3.1	4
284	Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. <i>Journal of Lipid Research</i> , 2010, 51, 1546-1553.	2.0	198
285	Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. <i>Journal of Lipid Research</i> , 2010, 51, 3055-3061.	2.0	76
286	Subclinical Myocardial Necrosis and Cardiovascular Risk in Stable Patients Undergoing Elective Cardiac Evaluation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 634-640.	1.1	24
287	Diabetic dyslipidemia: extending the target beyond LDL cholesterol. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, s20-s24.	3.1	11
288	The Metabolic Syndrome, Its Component Risk Factors, and Progression of Coronary Atherosclerosis. <i>Archives of Internal Medicine</i> , 2010, 170, 478.	4.3	114

#	ARTICLE	IF	CITATIONS
289	Findings of clinical trials that evaluate the impact of medical therapies on progression of atherosclerosis. <i>Current Medical Research and Opinion</i> , 2010, 26, 745-751.	0.9	1
290	Rationale and approach to evaluation of the impact of medical therapies on progression of atherosclerosis with arterial wall imaging. <i>Current Medical Research and Opinion</i> , 2010, 26, 737-744.	0.9	1
291	Clinical Predictors of Plaque Progression Despite Very Low Levels of Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2736-2742.	1.2	143
292	Intravascular Ultrasound-Derived Measures of Coronary Atherosclerotic Plaque Burden and Clinical Outcome. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2399-2407.	1.2	405
293	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. <i>Lancet</i> , The, 2010, 375, 1875-1884.	6.3	788
294	High-Density Lipoprotein and Progression Rate of Atherosclerosis in Intravascular Ultrasound Trials. <i>American Journal of Cardiology</i> , 2009, 104, 16E-21E.	0.7	7
295	Attenuated Plaque at Nonculprit Lesions in Patients Enrolled in Intravascular Ultrasound Atherosclerosis Progression Trials. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 672-678.	1.1	33
296	Low Levels of Low-Density Lipoprotein Cholesterol and Blood Pressure and Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1110-1115.	1.2	63
297	Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 85-93.	0.6	2
298	Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 753-761.	2.5	2
299	Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. <i>Atherosclerosis</i> , 2009, 204, 424-428.	0.4	81
300	Myeloperoxidase, modified lipoproteins, and atherogenesis. <i>Journal of Lipid Research</i> , 2009, 50, S346-S351.	2.0	168
301	Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries. <i>Current Opinion in Lipidology</i> , 2009, 20, 491-496.	1.2	16
302	Invasive Imaging Modalities and Atherosclerosis: The Role of Intravascular Ultrasound. , 2009, , 410-419.		1
303	Intravascular Ultrasound. , 2009, , 83-93.		0
304	Rosuvastatin and progression of atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 925-933.	0.6	8
305	Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling. <i>Journal of the American College of Cardiology</i> , 2008, 52, 255-262.	1.2	296
306	Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. <i>Atherosclerosis</i> , 2008, 196, 240-247.	0.4	79

#	ARTICLE	IF	CITATIONS
307	Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2008, 299, 1265.	3.8	463
308	Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2008, 299, 1547.	3.8	367
309	Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography. Circulation, 2008, 117, 2458-2466.	1.6	186
310	Response to Letters Regarding Article, "Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden"; Circulation, 2008, 118, .	1.6	0
311	Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2008, 299, 1561.	3.8	782
312	Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis. Circulation, 2008, 118, 2506-2514.	1.6	200
313	High-density lipoprotein and atheroma monitoring. Current Opinion in Cardiology, 2008, 23, 386-392.	0.8	1
314	HDL: still a target for new therapies?. Current Opinion in Investigational Drugs, 2008, 9, 950-6.	2.3	7
315	Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction. Circulation, 2007, 116, 2315-2324.	1.6	85
316	Exploring the natural history of atherosclerosis with intravascular ultrasound. Expert Review of Cardiovascular Therapy, 2007, 5, 295-306.	0.6	7
317	Effect of Torcetrapib on the Progression of Coronary Atherosclerosis. New England Journal of Medicine, 2007, 356, 1304-1316.	13.9	921
318	Effects of a Potent and Selective PPAR- $\alpha$ Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia. JAMA - Journal of the American Medical Association, 2007, 297, 1362.	3.8	121
319	Atherosclerosis imaging in drug development. Expert Opinion on Drug Discovery, 2007, 2, 1241-1250.	2.5	0
320	Impact of statins on atherosclerotic plaque. Future Cardiology, 2007, 3, 157-164.	0.5	1
321	Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2007, 298, 1180.	3.8	1,143
322	Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. JAMA - Journal of the American Medical Association, 2007, 297, 499.	3.8	654
323	$\beta$ -Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials. Annals of Internal Medicine, 2007, 147, 10.	2.0	83
324	New targets of high-density lipoprotein therapy. Current Opinion in Lipidology, 2007, 18, 421-426.	1.2	21

#	ARTICLE	IF	CITATIONS
325	Impact Of Statin Therapy On The Artery Wall In The Low-Risk Patient: Implications From The METEOR Study. <i>Future Lipidology</i> , 2007, 2, 595-601.	0.5	0
326	Coronary Artery Calcification and Changes in Atheroma Burden in Response to Established Medical Therapies. <i>Journal of the American College of Cardiology</i> , 2007, 49, 263-270.	1.2	125
327	Rate of Progression of Coronary Atherosclerotic Plaque in Women. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1546-1551.	1.2	71
328	Protein carbamylation links inflammation, smoking, uremia and atherogenesis. <i>Nature Medicine</i> , 2007, 13, 1176-1184.	15.2	601
329	Comparison of Coronary Atherosclerotic Volume in Patients With Glomerular Filtration Rates $\leq 60$ Versus $>60$ ml/min/1.73 m <sup>2</sup> : A Meta-Analysis of Intravascular Ultrasound Studies. <i>American Journal of Cardiology</i> , 2007, 99, 813-816.	0.7	28
330	Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 266-273.	2.0	11
331	Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 290-295.	0.8	0
332	Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis. <i>New England Journal of Medicine</i> , 2006, 354, 1253-1263.	13.9	368
333	Paradoxical increase in lumen size during progression of coronary atherosclerosis: Observations from the REVERSAL trial. <i>Atherosclerosis</i> , 2006, 189, 229-235.	0.4	42
334	Relationship Between Atheroma Regression and Change in Lumen Size After Infusion of Apolipoprotein A-I Milano. <i>Journal of the American College of Cardiology</i> , 2006, 47, 992-997.	1.2	141
335	Relationship Between Cardiovascular Risk Factors and Atherosclerotic Disease Burden Measured by Intravascular Ultrasound. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1967-1975.	1.2	142
336	Consumption of Saturated Fat Impairs the Anti-Inflammatory Properties of High-Density Lipoproteins and Endothelial Function. <i>Journal of the American College of Cardiology</i> , 2006, 48, 715-720.	1.2	180
337	Effects of Normal, Pre-Hypertensive, and Hypertensive Blood Pressure Levels on Progression of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2006, 48, 833-838.	1.2	168
338	Intravascular ultrasound assessment of novel antiatherosclerotic therapies: Rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. <i>American Heart Journal</i> , 2006, 152, 67-74.	1.2	27
339	The ACTIVATE study: lessons for the future of atherosclerotic therapy. <i>Future Lipidology</i> , 2006, 1, 421-428.	0.5	0
340	Application of intravascular ultrasound in anti-atherosclerotic drug development. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 485-492.	21.5	43
341	High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. <i>Cell Research</i> , 2006, 16, 799-808.	5.7	19
342	Recent trends in coronary intravascular ultrasound: Tracking atherosclerosis, pursuit of vulnerable plaques, and beyond. <i>Journal of Nuclear Cardiology</i> , 2006, 13, 91-96.	1.4	6

#	ARTICLE	IF	CITATIONS
343	Effects of Obesity on Lipid-Lowering, Anti-Inflammatory, and Antiatherosclerotic Benefits of Atorvastatin or Pravastatin in Patients With Coronary Artery Disease (from the REVERSAL Study). <i>American Journal of Cardiology</i> , 2006, 97, 1553-1557.	0.7	64
344	Emerging Role of Intravascular Ultrasound in the Assessment of Experimental Anti-Atherosclerotic Therapies. <i>Current Medicinal Chemistry</i> , 2006, 13, 1727-1734.	1.2	3
345	Intravascular Ultrasound in Cardiovascular Medicine. <i>Circulation</i> , 2006, 114, e55-9.	1.6	49
346	Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1556.	3.8	1,759
347	Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy. <i>Circulation</i> , 2006, 113, 2826-2834.	1.6	145
348	The ASTEROID trial: coronary plaque regression with high-dose statin therapy. <i>Future Cardiology</i> , 2006, 2, 651-654.	0.5	21
349	Coronary atherosclerosis can regress with very intensive statin therapy.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 937-944.	0.6	40
350	High-density lipoproteins as therapeutic targets. <i>Current Opinion in Lipidology</i> , 2005, 16, 345-349.	1.2	36
351	Formation of Dysfunctional High-Density Lipoprotein by Myeloperoxidase. <i>Trends in Cardiovascular Medicine</i> , 2005, 15, 212-219.	2.3	138
352	Reconstituted High-Density Lipoproteins Inhibit the Acute Pro-Oxidant and Proinflammatory Vascular Changes Induced by a Periarterial Collar in Normocholesterolemic Rabbits. <i>Circulation</i> , 2005, 111, 1543-1550.	1.6	275
353	Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2416-2421.	1.1	146
354	Myeloperoxidase and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1102-1111.	1.1	653
355	Quantification of 3-â€Nitrotyrosine Levels Using a Benchtop Ion Trap Mass Spectrometry Method. <i>Methods in Enzymology</i> , 2005, 396, 245-266.	0.4	23